About Milamend
Milamend is a company based in Irving (United States) founded in 2023 by Camila Magnan, Lucas Labelle, and Mila Magnani. Milamend has raised $1.5 million across 1 funding round. Milamend offers products and services including Hormone Balance, Fertility Support, Thyroid Support, Mood and Sleep Support, and Digestive Support. Milamend operates in a competitive market with competitors including Gynoveda, Aptorum Group, DOMMA, MidwayBiome and Amberen, among others.
- Headquarter Irving, United States
- Founders Camila Magnan, Lucas Labelle, Mila Magnani
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.5 M (USD)
in 1 rounds
-
Latest Funding Round
$1.5 M (USD), Seed
Sep 06, 2024
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Milamend
Milamend offers a comprehensive portfolio of products and services, including Hormone Balance, Fertility Support, Thyroid Support, Mood and Sleep Support, and Digestive Support.
Powdered blend for supporting hormone balance and overall health.
Ingredients to enhance reproductive health and hormone regulation.
Formulation aiding thyroid function and metabolic balance.
Blend for improving mood stability and sleep quality.
Components promoting gut health and reducing bloating.
Funding Insights of Milamend
Milamend has successfully raised a total of $1.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.5 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Milamend
Investment portfolio details for Milamend
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Milamend
Detailed financials for Milamend
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Milamend Comparisons
Peer comparison for Milamend
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Milamend
Milamend operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gynoveda, Aptorum Group, DOMMA, MidwayBiome and Amberen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Dietary supplements and Ayurvedic solutions for women's health are offered.
|
|
| Locked | Locked | Locked |
Developer of small molecular therapeutics for multiple disorders
|
|
| Locked | Locked | Locked |
Supplements and functional foods for women's menopause health are developed.
|
|
| Locked | Locked | Locked |
Developer of a proprietary daily dietary supplement to enhance bone health in post-menopausal women
|
|
| Locked | Locked | Locked |
Menopause relief supplements are provided by Amberen for symptom management.
|
|
| Locked | Locked | Locked |
Functional foods for women's health improvement are provided.
|
Detailed competitors of Milamend
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Milamend
Complete news archive for Milamend
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Milamend
Milamend was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Milamend is headquartered in Irving, United States. It is registered at Irving, Texas, United States.
Milamend is a funded company, having raised a total of $1.5M across 1 funding round to date.
Milamend was established in 2023 in Irving, United States, as a wellness brand targeting womens hormonal health. Specialized drink formulations are provided to address imbalances, including those associated with conditions such as PCOS. Operations focus on the health and wellness sector, with products designed for women experiencing related symptoms. The company is led by co-founders Camila Magnan, Lucas Labelle, and Mila Magnani.
Milamend's top competitors include Gynoveda, Aptorum Group and DOMMA.
Milamend offers Hormone Balance, Fertility Support, Thyroid Support, Mood and Sleep Support, and Digestive Support.